LNTH-2403

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameLNTH-2403
Drug Alias NameLNTH-2403
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive therapeutic agent
Mechanisms of ActionAnti-LRRC15
TargetsLeucine-rich repeat-containing protein 15
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLantheus
China Registration ClassN/A

Develop Information

Active CompaniesLantheusRadiopharm Theranostics LtdLantheus Medical Imaging Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A